Skip to main content
BioThera Solutions

Topical, microneedling or injectable: what sterility and endotoxin testing tell you about an EV (exosome) product

The same vial of extracellular vesicles can be a reasonable cosmetic and an unsafe injectable. What separates them is not the vesicles. It is sterility, endotoxin, and the regulatory class the product was made for.

FS

Frédéric St-Denis-Bissonnette, PhD

Founder & CEO, BioThera Solutions

Clinics and distributors increasingly ask a simple question about extracellular vesicle (EV, often marketed as exosome) products: can this one go under the skin? The answer depends on three things the vesicles themselves do not determine. Is the product sterile? How much endotoxin does it carry? And which regulatory class was it made and labelled for?

Topical, microneedling and injection are different exposures

A topical cosmetic is applied to intact skin. The stratum corneum, the outermost layer of dead, tightly packed cells, is the barrier that makes this safe: microbes and molecules on the surface mostly stay on the surface.

Microneedling removes that assumption. The needles create thousands of channels through the stratum corneum, so anything applied during or right after the procedure reaches living tissue. Injection goes further and places the material directly into the dermis, muscle or joint. Each step down in depth raises the bar for what the product must be shown to be free of.

That is why the label matters as much as the vial. A product made and tested as a cosmetic has been shown to be suitable for intact skin. It has not been shown to be suitable for open skin or injection, however carefully it was made.

What "sterile" actually means

Sterile is a regulatory claim, not a description of how clean a process feels. To call a product sterile, a manufacturer has to use a validated sterilization or aseptic process and pass a formal sterility test, such as the one described in the United States Pharmacopeia chapter on sterility testing. A process that removes bacteria very effectively is not the same thing until that has been demonstrated.

Cosmetics are not required to be sterile. They are required to meet microbial limits: a cap on the total number of aerobic microorganisms, yeasts and moulds per gram, and the absence of specified harmful organisms. Those limits are appropriate for intact skin. They are not a sterility claim.

What endotoxin is, and why it matters for open skin

Endotoxin, also called lipopolysaccharide (LPS), is a component of the outer membrane of Gram-negative bacteria. It survives after the bacteria are gone, so a product can contain endotoxin even when no living bacteria remain. In the bloodstream or in tissue, small amounts trigger fever and inflammation. On intact skin, it largely stays outside the body.

Two families of tests measure it. The traditional Limulus amebocyte lysate (LAL) assay uses a reagent from horseshoe crab blood. Recombinant Factor C (rFC) assays use a lab-made version of the same detection protein and avoid animal-derived reagents. Both report endotoxin in endotoxin units (EU) per millilitre or per milligram.

For injectables, pharmacopeias set strict endotoxin limits tied to the dose and the route. For a cosmetic, there is no equivalent requirement. That difference is the whole reason a cosmetic EV product and an injectable EV product are not interchangeable.

Same vial, different product: why the use changes the regulatory class

In most jurisdictions, a product is classified by how it is used and what is claimed for it, not only by what is in it. The same EV material that is a cosmetic on intact skin stops being a cosmetic once it is used for microneedling or injection, or sold with claims to treat or repair. It then needs a higher level of regulatory authorization than a cosmetic notification.

Canada shows how this works in practice:

  • Cosmetic. Applied to intact skin, with cosmetic claims only. Requires a cosmetic notification to Health Canada, not a pre-market approval.
  • Natural health product. A plant-derived product used on the skin with health claims, such as supporting skin recovery, can fall under the Natural Health Products Regulations. That route requires a product licence and evidence for each claim, and in exchange allows the authorized health claims a cosmetic cannot make.
  • Drug or biologic. Anything administered by puncturing the dermis, which includes injection, is explicitly excluded from the natural health product framework and is regulated as a drug or biologic, with clinical evidence and manufacturing standards to match.

The United States draws a similar line. The FDA has stated that exosome products intended to treat diseases or conditions in people are regulated as drugs and biological products that need premarket review and approval, and that no exosome product had been approved.

For a buyer, the practical consequence is straightforward. A product sold as a cosmetic is a topical product for intact skin. Using it for microneedling or injection takes it outside what it was made, tested and notified for, whatever the vial looks like.

Questions to ask before any EV product touches open skin

  • Is the product labelled and notified as a cosmetic, or authorized as a drug or biologic?
  • Is it represented as sterile, and by which validated method and test?
  • Is endotoxin measured on each batch, by which assay (LAL or rFC), and against what acceptance limit?
  • What microbial limits does the Certificate of Analysis report, and are they results or just specifications?
  • Does the label or Certificate of Analysis restrict the route of use?

A supplier that answers these specifically is giving you the information you need. A supplier that answers "it is very pure" is not.

How BioThera's material is tested and labelled

BioThera's current plant-derived EV material is made for topical cosmetic use. Every batch has its own Certificate of Analysis, which reports, among other results:

  • particle concentration and size distribution by Nanoparticle Tracking Analysis (NTA), and particle-to-protein ratio;
  • pH (specification 5 to 6);
  • total aerobic microbial count (no more than 1,000 CFU/g) and total yeast and mould count (no more than 100 CFU/g);
  • mycoplasma by PCR (specification: absent);
  • endotoxin, measured by recombinant Factor C and reported on each batch. No acceptance limit has been set, because the material is not intended for injection.

The material is not represented as sterile, and the Certificate of Analysis states it plainly: for cosmetic topical use only, not for injection or microneedling. Testing is currently performed in-house, and BioThera is selecting a third-party laboratory to independently validate the testing behind its Certificate of Analysis.

Any future use on open skin, including post-procedure applications, will go through the clinical and regulatory work that class of use requires. Until then, BioThera does not recommend its material for microneedling or injection. The post-procedure article sets out what can and cannot be said about that area today.

The implication for buyers

The vesicles are only half of the product. The other half is the documentation that says where it is safe to put them. Ask for both, and treat a missing endotoxin result or an unqualified sterility claim as an answer in itself.

Sample Certificates of Analysis are available on request from the Resources page.

Want more EV science in your Google results?

Add BioThera Solutions as a preferred source on Google

Primary sources

  1. U.S. Food and Drug Administration. Public Safety Notification on Exosome Products., 2019. www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products
  2. Welsh JA, et al. (incl. St-Denis-Bissonnette F). Minimal information for studies of extracellular vesicles (MISEV2023). Journal of Extracellular Vesicles, 2024. doi.org/10.1002/jev2.12404
  3. Health Canada. Cosmetics: guidance and notification., 2024. www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics.html
  4. Government of Canada. Natural Health Products Regulations (SOR/2003-196), Schedule 2: Excluded Natural Health Product Substances.. laws-lois.justice.gc.ca/eng/regulations/SOR-2003-196/

Questions on this topic?

Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel.

BioThera Solutions

A fully integrated extracellular vesicle company, from research and intellectual property to manufacturing, with a process designed to scale. Extracellular vesicles (EVs/exosomes) are among biology's most promising delivery systems, and we are building the infrastructure the field has been missing.

Ottawa, Ontario, Canada
477-150 Louis-Pasteur Private Ottawa, Ontario K1N 9B4 Canada
Add BioThera Solutions as a preferred source on Google

© 2026 BioThera Solutions Inc. All rights reserved.

For informational purposes only. Nothing on this website is medical advice. BioThera develops and manufactures characterized extracellular vesicles (exosomes) and, for cosmetic applications, licenses its technology exclusively to Vesera™, a skincare company and BioThera subsidiary. Vesera™ products are cosmetics and are not intended to diagnose, treat, cure, or prevent any disease. BioThera does not sell products to consumers, and its work on therapeutic applications is research only.